DAN-222 is under clinical development by Dantari and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to GlobalData, Phase II drugs for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DAN-222’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DAN-222 is under development for the treatment of HER2-negative metastatic breast cancer. The therapeutic candidate is polymeric nanoparticle conjugated with camptothecin and is administered by intravenous route.
Dantari is a biotechnology company committed to creating breakthrough medicines for the treatment of cancer and other serious diseases. Dantari is headquartered in Thousand Oaks, California, the US.
For a complete picture of DAN-222’s drug-specific PTSR and LoA scores, buy the report here.